Protein kinase C activation down-regulates natriuretic peptide receptor C expression via transcriptional and post-translational pathways  by Yanaka, Noriyuki et al.
FEBS 19554 FEBS Letters 418 (1997) 333-336 
Protein kinase C activation down-regulates natriuretic peptide receptor C 
expression via transcriptional and post-translational pathways 
Noriyuki Yanaka, Hiroyuki Akatsuka, Kenji Omori* 
Lead Generation Research Laboratory, Tanabe Seiyaku Co., Ltd., 16-89 Kashima-3-chome, Yodogawa-ku, Osaka 532, Japan 
Received 2 October 1997; revised version received 30 October 1997 
Abstract Natriuretic peptide receptor C (NPR-C) mRNA 
expression and ANP-binding activity via NPR-C are signifi-
cantly down-regulated in HeLa cells with phorbol myristate 
acetate (PMA) treatment. Stabilization of the NPR-C mRNA 
by PMA indicated that down-regulation of its mRNA was 
mediated through negative transcriptional regulation. Despite the 
significant loss of the mRNA, reduction of NPR-C-specific 
ANP-binding activity after PMA exposure (4 h) was accom-
panied by a slight decrease in total NPR-C protein (with a 5% 
loss) and was also produced in the presence of actinomycin D or 
cycloheximide. The inhibitory effect of a long PMA exposure 
(18 h) paralleled with a decrease in total NPR-C protein is 
suggested to be dependent on reduction of de novo NPR-C 
synthesis. PMA-induced transcriptional and post-translational 
down-regulation of NPR-C was effectively reversible in the 
presence of the protein kinase C inhibitor GF109203X. These 
findings demonstrate that protein kinase C activation down-
regulated NPR-C expression through transcriptional and post-
translational pathways and that immediate functional receptor 
loss was mediated via a post-translational mechanism, such as 
enhanced receptor internalization. 
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1. Introduction 
Natriuretic peptides (NPs) are known to play important 
roles in cardiovascular homeostasis. Three isoforms, termed 
atrial natriuretic peptide (ANP), brain natriuretic peptide 
(BNP) and C-type natriuretic peptide (CNP) [1,2], constitute 
the natriuretic peptide family. ANP and BNP are considered 
to be responsible for systemic blood pressure control and 
body fluid homeostasis [3,4]. In contrast, CNP has recently 
been demonstrated to be involved in the suppression of vas-
cular smooth muscle cells proliferation and in the phenotypic 
development of osteoblasts [5]. These biological functions of 
NPs are mediated via intracellular production of guanosine 
3',5'-cyclic monophosphate (cGMP) through guanylyl cyclase 
(GC)-coupled receptors, termed GC-A and GC-B. Natriuretic 
peptide receptor C (NPR-C) putatively has a very short intra-
cytoplasmic domain which lacks guanylyl cyclase activity [6-
8]. While this receptor supposedly regulates the biological ef-
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fects of NPs by elimination from the circulation, NPR-C has 
also been reported to control directly adenylyl cyclase activity 
via a Gi protein, phospholipid hydrolysis, thymidine kinase 
activity and mitogen-activated protein kinase activity in the 
absence of intracellular cGMP production [9-13]. 
Several significant studies have been done on characterizing 
NPR-C expression in vitro and in vivo. Increases in intracel-
lular cAMP and cGMP concentrations have been shown to 
inhibit NPR-C gene expression [14,15], whereas down-regula-
tion of the receptor in the lungs of rats adapted to hypoxia, in 
the kidneys of rats with renal failure and streptozotocin-in-
duced diabetes mellitus, and in the aorta of hypertensive rats 
has been reported [16-19]. The pathophysiological loss of the 
NPR-C protein is suggested to reduce the elimination rate of 
NPs. Although NPR-C has been demonstrated to localize in 
the tracheal and glomerular epithelium [20-22] by immuno-
histological studies, no information is yet available on the 
mechanisms underlying the down-regulation of NPR-C ex-
pression. 
Here, we show that protein kinase C activation significantly 
and independently down-regulates NPR-C mRNA expression 
and NPR-C-dependent ANP-binding activity in human epi-
thelial-like cells via transcriptional and post-translational reg-
ulation. We recently reported highly specific antisera that rec-
ognize the NPR-C cytoplasmic domain [22], and the 
availability of these antisera enabled us to investigate NPR-
C expression at the total protein level. 
2. Materials and methods 
2.1. Materials 
Restriction endonucleases and DNA-modifying enzymes were ob-
tained from Takara Shuzo (Kyoto, Japan). [a-32P]dCTP, [125I]human 
ANP and Hybond-N+ nylon filter were from Amersham. Human 
ANP was purchased from The Peptide Institute (Osaka, Japan). 
The ANP analog, des[Gln,8,Ser19,Gly20,Leu21,Gly22]ANP-(4-23)-
NH2 (C-ANF(4-23)), and bovine serum albumin (fraction V) were 
purchased from Sigma. Dulbecco's modified Eagle's medium 
(DMEM) and fetal bovine serum (FCS) were obtained from Gibco 
Laboratories. GF109203X was purchased from Calbiochem (USA). 
2.2. Cell cultures and transient cell transfection 
HeLa cells, purchased from Dainippon Pharmaceutical Co. (Osaka, 
Japan), were cultured in DMEM supplemented with 10% FCS and 
passaged in a controlled atmosphere of 5% C02/95% air at 37°C. 
HeLa cells were washed twice with PBS and incubated in DMEM 
containing 0.1% bovine serum albumin with phorbol myristate acetate 
(PMA, 20 ng/ml) for 2 h, 4 h or 18 h. 
2.3. Binding assay of NPR-C 
HeLa cells in 24-well dishes were washed twice with 1 ml of PBS. 
Binding of 0.5 nM [125I]human ANP was allowed to proceed in 
DMEM containing 0.1'% bovine serum albumin for 30 min at 4°C 
to equilibrium in the presence or absence of unlabeled C-ANF(4-23) 
(1 uM) (n = 4). After 30 min, cells were washed twice with PBS and 
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Fig. 1. RNA analysis by Northern blot hybridization. Hybridization 
was carried out with a fragment of human NPR-C cDNA as a 
probe as described in Section 2. A: HeLa cells were incubated for 
4 h in the presence or absence of PMA. 5 |xg of poly(A)+ RNA 
was subjected to Northern blotting analysis. The filter was subjected 
to autoradiography for 16 h. B: HeLa cells were incubated for 
30 min with actinomycin D (5 ug/ml) prior to treatment with PMA. 
5 ug of poly(A)+ RNA of the indicated time was prepared for 
Northern blot analysis. The filter was subjected to autoradiography 
for 72 h. 
bilon P filter (Millipore) for immunodetection. The blots were blocked 
by soaking in 5% non-fat dried milk in PBS and incubated with anti-
NPR-C antiserum (diluted 1:1000) for 18 h at 4°C. Signals were 
detected with horseradish peroxidase-conjugated anti-rabbit immuno-
globulin G and the enhanced chemiluminescence system (Amersham). 
2.5. RNA analysis by Northern blot hybridization 
Total RNA was isolated from HeLa cells using Isogen (Nippon 
gene, Toyama, Japan), and poly(A)+ RNA was purified by oli-
go(dT)-cellulose column chromatography using mRNA separator kit 
(Clontech). 5 (ig of poly(A)+ RNA was fractionated in a 1% agarose 
gel containing 0.66 M formaldehyde and 0.02 M morpholinopropa-
nesulfonic acid (pH 7.0). Fractionated RNAs were transferred onto a 
nylon filter by capillary blotting and then crosslinked by UV irradi-
ation. A 32P-labeled cDNA fragment encoding human NPR-C or 
glyceraldehyde phosphate dehydrogenase (GAPDH) was used for 
Northern blot hybridization as probes. The filter was washed three 
times in 1 XSSC, 0.1% SDS at 55°C for 30 min each and subjected to 
autoradiography for the indicated times. 
2.6. Statistical analysis 
All values are expressed as mean ± S.D. Statistical significance was 
determined by the unpaired Student's /-test. 
solubilized with 500 ul of 0.5 N NaOH. Aliquots were assayed for 
radioactivity using a Cobra y-counter (Packard). 
2.4. Western blot (immunoblot) analysis 
The antiserum against the NPR-C protein used was obtained by the 
following procedure as reported previously [22]. Mitogen-activated 
protein (MAP)-peptide complex containing the sequence (NH2-
RKKYRITIERRNHQEESNIGKHRELREDSIRSHFSVA-COOH), 
derived from the cytoplasmic domain of rat NPR-C protein, was 
synthesized by the 9-fluorenylmethyloxycarbonyl synthesis strategy. 
Polyclonal antibody toward the peptide was obtained by injecting 
rabbits with the peptide in Freund's complete adjuvant. HeLa cells 
were homogenized in 3 ml of buffer A (10 mM Tris (pH 7.5), 5 mM 
EDTA, 5 uM leupeptin, 2 mM dithiothreitol (DTT), and 0.2 mM 
phenylmethylsulfonyl fluoride (PMSF)). After centrifugation for 
30 min at 5000 Xg at 4°C, the resulting supernatants were centrifuged 
for 30 min at 40000Xg at 4°C. 20 |xg of the precipitates re-suspended 
in 200 ul of buffer A were subjected to SDS-PAGE (10% polyacryl-
amide). The proteins were electrophoretically transferred to an Immo-
3. Results 
N P R - C m R N A expression was significantly down-regulated 
in HeLa cells treated with P M A (Fig. 1A). The steady-state 
m R N A level as determined above can be affected by the rate 
of m R N A degradation as well as by that of gene transcrip-
tion. Nor thern blot analysis has demonstrated that the N P R -
C m R N A was significantly increased by P M A stimulation in 
HeLa cells in the presence of actinomycin D (5 Ug/ml), indi-
cating that P M A enhanced the stability of N P R - C m R N A 
(Fig. IB). This result suggested that the decrease in the 
N P R - C m R N A level was closely associated with transcrip-
tional suppression but not with enhanced degradation of its 
m R N A . However, promoter analysis using human and mouse 
N P R - C promoter-luciferase constructs in HeLa cells indicated 
that no significant decrease of transcriptional activity was ob-
served using PMA, suggesting that the 5'-flanking regions of 
the human N P R - C gene (from —1332 to +13) and the mouse 
N P R - C gene (from —9 k to +112) were not responsible for the 
transcriptional regulation (data not shown). 
To estimate the N P R - C protein level directly, we performed 
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Fig. 2. Western blot analysis and ANP-binding assay using actino-
mycin D and cycloheximide. A: HeLa cells were incubated for 4 h 
in the presence or absence of PMA. Western blot analysis was car-
ried out as described in Section 2. C = positive control, 45 ug of 
membrane protein from rat lung. B: After HeLa cells were incu-
bated for 30 min with actinomycin D (5 ug/ml) or cycloheximide 
(5 ug/ml), cells were incubated for 4 h in the presence or absence of 
PMA. **P<0.01 compared with basal. 
Fig. 3. Effect of a long exposure to PMA on NPR-C expression. 
A: HeLa cells were incubated for 18 h in the presence or absence 
of PMA. 5 u,g of poly(A)+ RNA was subjected to Northern blot 
analysis and hybridization was carried out with a fragment of hu-
man NPR-C cDNA as a probe. B: Western blot analysis and ANP-
binding assay were carried out as described in Section 2. *P<0.05 
compared with basal. 
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Fig. 4. Effect of protein kinase C inhibitor on NPR-C down-regula-
tion. HeLa cells were incubated for 2 h, (lane 1) in the absence of 
PMA; (2) in the presence of PMA; (3) in the presence of PMA and 
GF109203X (0.1 uM); (4) in the presence of PMA and GF109203X 
(1 uM). A: HeLa cells were incubated with 0.5 nM [125I]human 
ANP in the presence or absence of the unlabeled C-ANF(4—23) as 
described in Section 2. B: 5 ug of poly(A)+ RNA was subjected to 
Northern blot analysis. *P < 0.05 compared with basal. 
Western blot analysis using the antibody against the rat NPR-
C cytoplasmic domain (Fig. 2A). At the reducing condition, 
the solubilized NPR-C protein was detected as a single band 
of approximately 63 kDa. PMA treatment for 4 h strongly 
reduced the level of NPR-C mRNA, and the NPR-C protein 
level was demonstrated to be slightly decreased by Western 
blot analysis (Fig. 2A). Surprisingly, the ANP-binding activity 
was significantly diminished by the treatment with PMA (Fig. 
2B). Neither actinomycin D (5 ug/ml) nor cycloheximide (5 ixg/ 
ml) affected the reduction of ANP-binding activity following 
4 h PMA treatment (Fig. 2B). These results indicate that this 
down-regulation of functional receptor was not dependent on 
reduction of its mRNA and but that post-translational mech-
anisms including enhanced receptor internalization are likely 
to be involved in the inhibitory effect of PMA treatment for 
4 h on ANP-binding activity. A subsequent experiment using 
18 h exposure to PMA resulted in significant decreases in 
mRNA and protein level (62% and 64% inhibition, respec-
tively) in HeLa cells (Fig. 3), accompanied by a decrease in 
functional receptor level. These results suggest that NPR-C 
down-regulation after a longer exposure to PMA is attribut-
able to transcriptional down-regulation. Furthermore, PMA-
mediated transcriptional and post-translational down-regula-
tion of NPR-C was dose-dependently blocked by the PKC-
specific inhibitor GF109203X, demonstrating that PKC acti-
vation caused down-regulation of NPR-C expression through 
transcriptional and post-translational pathways (Fig. 4A,B). 
The PMA effect on ANP binding was not inhibited by the 
tyrosine kinase inhibitor genistein (data not shown). 
4. Discussion 
Here, we investigated mechanisms governing the down-reg-
ulation of NPR-C expression. In animal models as described 
above, serious injuries are presumed to be initiated and devel-
oped by cytokines and growth factors which are synthesized 
and secreted by various cell types including monocyte-macro-
phages, lymphocytes and vascular endothelial cells, indicating 
that PKC signaling was enhanced in several cells involved in 
pathophysiological aspects. The current study has demon-
strated that PMA-activating PKC reduced the NPR-C 
mRNA level and NPR-C-mediated ANP-binding activity. In 
addition, the decrease of the NPR-C-dependent ANP-binding 
activity by exposure to PMA for 4 h was also produced in the 
presence of actinomycin D or cycloheximide, suggesting that 
this PMA-induced reduction was independent of de novo syn-
thesis of new NPR-C proteins. In contrast, the inhibitory 
effect of PMA treatment for 18 h was paralleled by a decrease 
in total NPR-C protein level, suggesting that PMA-dependent 
reduction of functional receptor activity after a long exposure 
was mainly dependent on a transcriptional mechanism. The 
present studies demonstrated that down-regulation of NPR-C 
expression by PMA was mediated through two distinct path-
ways. Recent studies have shown that rapid down-regulation 
of type IB angiotensin II receptor and basic FGF receptor 
was induced by PKC activation [23,24]. PMA has been dem-
onstrated to have effects on cell function independent of the 
effects via PKC activation; however, PMA-induced transcrip-
tional and post-translational down-regulation of NPR-C were 
effectively reversible in the presence of a specific PKC inhib-
itor, suggesting that PKC activation caused down-regulation 
of NPR-C expression through both transcriptional and post-
translational pathways. 
We previously cloned and characterized in detail the 5'-
flanking regulatory regions of the mouse and human NPR-
C genes, and AP-1 elements responsible for PMA action have 
been identified in the 5'-flanking regions of the mouse and 
human NPR-C genes [25,26]. However, transient expression 
analyses using NPR-C promoter-luciferase constructs in HeLa 
cells demonstrated no significant decrease of transcriptional 
activity by PMA treatment, suggesting that responsible ele-
ment(s) mediating the PMA inhibitory effect were located fur-
ther upstream or downstream in the NPR-C gene locus. In 
contrast, PMA prolonged the half-life of NPR-C mRNA, 
suggesting that PMA signaling blocked ribonuclease recogni-
tion. PMA has been shown to stabilize a variety of cytokine 
and other mRNAs, presumably through activation of PKC-
mediated signal transduction cascades [27,28]. AUUUA mo-
tifs in human GM-CSF mRNA are reported to play an im-
portant role in stabilizing the mRNA by PMA treatment [29], 
suggesting that stabilization of the NPR-C mRNA was per-
formed by a similar mechanism. However, full-length human 
NPR-C cDNA has not been isolated and, therefore, it is un-
clear whether the NPR-C mRNA possesses the AUUUA mo-
tif. Further experiments will be required to elucidate the 
PMA-dependent repression of the NPR-C gene transcription 
and stabilization of its mRNA. 
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